Myocardial Ischemia
Conditions
Brief summary
The goal of the main trial was to evaluate the effect of low dose hormone replacement therapy with 1 mg norethindrone/10mcg ethinyl estradiol in postmenopausal women with a history of chest discomfort, myocardial ischemia and no obstructive CAD. For the purposes of this study as a core lab coordinating center, the investigators will be performing P31 MRS core lab analyses; hormone core lab analyses; lipid core lab analyses; glucose, insulin and HOMA core lab analyses; exercise stress test/Holter monitor core lab analyses; brachial artery reactivity test core lab analyses; full study data analyses for manuscript preparation and the writing and submission and publication of manuscript. The main trial duration: December 1999 - May 2003. The ancillary data analysis project duration: April 2006 - March 2010.
Detailed description
See Brief Summary above.
Interventions
Hormone replacement therapy with 1 mg norethindrone/10 mcg thinyl estradiol (1/10 NA/EE)
1 mg placebo
Sponsors
Study design
Eligibility
Inclusion criteria
* Postmenopausal WISE and nonWISE study participants * Normal/minimally diseased coronary arteries (\<50% luminal diameter stenosis in all epicardial coronary arteries) within 36 months of ancillary study entry and no intercurrent MI, PTCA, CABG * Any one (or multiple) of the following criteria suggestive of myocardial ischemia within 36 months of ancillary study entry: 1. Abnormal P-31 magnetic resonance spectroscopy (a fall in quantitative PCr/ATP ratio \>15% from control) performed at a WISE or nonWISE site 2. Positive exercise stress test (\> or = 1mm horizontal or downsloping, or \> or =1.5mm upsloping ST segment depression measured 0.08 msec after the J point), performed and/or interpretated by a WISE or WISE ancillary ancillary trial investigator 3. Reversible stress radionuclide perfusion defect \> equivocal and not attributable to breast/imaging artifact. performed as part of the WISE protocol 4. Coronary artery flow reserve \<2.25 performed. as part of using the WISE protocol * No contraindications to 12 weeks of FemHRT or hormone replacement therapy * Normal mammogram and pelvic exam (including PAP smear for those with an intact uterus) within 12 months of study entry * Documented normal liver function testing (SGOT) within 3 months of study entry.
Exclusion criteria
* Documented myocardial infarction, coronary artery bypass surgery or mechanical revascularization * Systolic blood pressure \>200 mmHg or diastolic blood pressure \>105 mmHg * LDL-cholesterol \>190 mg/dl, triglycerides \> or = 300 mg/dl * Clinically significant hepatic or renal dysfunction (SGOT more than 1.2 times normal at baseline, serum creatinine \>2) * Uncontrolled diabetes mellitus (FBS \> or = 225 mg/dl) or new onset diabetes until stabilized * Clinically significant valvular heart disease, dilated cardiomyopathy, or congestive heart failure (NYHA Class IV or severe Class III) * Currently on hormone replacement therapy and unwilling/unable to withdraw treatment prior to study, (participants are eligible for study entry 4-8 weeks following hormone replacement therapy withdrawal, at the discretion of the WISE ancillary trial Principal Investigator) * Previous breast cancer, mammogram suggestive of cancer, or endometrial cancer without hysterectomy * Abnormal uterine bleeding or abnormal Pap smear (SIL I, II or III, carcinoma in situ, or cancer) * Previous deep venous thrombosis, pulmonary embolism, or other thromboembolic disorder. * Alcoholism or drug abuse * Participation in any other investigational drug or device study Women with elevated diastolic (\> or = 90 mm Hg) or systolic (\> or = 140 mm Hg) blood pressure, LDL-cholesterol (\> or = 160 mg/dl), fasting blood sugar (\> or = 130 mg/dl) and women who smoke cigarettes will be told their risk factor levels and referred for evaluation and treatment by their private physician.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Inducible Myocardial Ischemia | Baseline | Inducible myocardial ischemia measured by P-31 gated magnetic resonance cardiac spectroscopy (MRS) is reported as change (∆) in PCr/ATP ratio, with isometric submaximal handgrip stress. PCr/ATP ratio defined as (stress-\[average of rest and recovery periods\]) / average of rest and recover periods X 100, and expressed as % mean ± SD. For this trial, myocardial ischemia was pre-specified as a fall in quantitative PCR/ATP ratio \>20% from rest, and a lower value is considered indicative of greater ischemia. |
| Endothelial Dysfunction (FMD) | Baseline | Endothelial dysfunction refers to altered vasoactive, anticoagulant, and anti-inflammatory properties of endothelium, and dysregulated vascular growth remodeling that results from a loss of nitric oxide (NO) bioactivity in the endothelium. Brachial Artery Reactivity Testing (BART), high-frequency ultrasonographic imaging of the brachial artery, evaluates flow-mediated vasodilation (FMD), an endothelium-dependent function. The technique provokes the release of nitric oxide, resulting in vasodilation that can be quantitated as an index of endothelial dysfunction. Flow-mediated vasodilation is typically expressed as the change in post-stimulus diameter as a percentage of the baseline diameter \[diameter after cuff deflation - baseline diameter / baseline diameter) x 100\]. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quality of Life - Health Survey | Baseline | Quality of life assessed by cardiac symptoms and psychological questionnaires (SF 36 scale - Short Form Health Survey) The SF-36 includes one multi-item scale that assesses eight health concepts: 1) limitations in physical activities because of health problems; 2) limitations in social activities because of physical or emotional problems; 3) limitations in usual role activities because of physical health problems; 4) bodily pain; 5) general mental health (psychological distress and well-being); 6) limitations in usual role activities because of emotional problems; 7) vitality (energy and fatigue); and 8) general health perceptions. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. |
| Physical Functional Disability - Functional Capacity (Metabolism Equivalents) | Baseline | Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. |
| Physical Functional Disability - Functional Capacity (METs) | Baseline | Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. A MET is defined as the resting metabolic rate, that is, the amount or oxygen consumet at rest, sitting quietly in a chair, approximately 3.5 ml O2 / kg / min (1.2 kcallmin for a 70-kg person). As such, work at METs requires twice the resting metabolism or 7.0 ml O2/kg/min, and so on. |
| Physical Functional Disability - Functional Capacity (Stress Induced ST Segment Depression) | Exit (12 weeks) | Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. In electrocardiography, the ST segment connects the QRS complex and the T wave and has duration of 80 to 120 ms. It should be essentially level with the PR and TP segment. The normal ST segment has a slight upward concavity. Flat, downsloping, or depressed ST segment may indicate coronary ishcemia. Positive treadmill exercise stress test (\>1.0 mm horizontal / downsloping or \>1.5 upsloping ST segment depression measured 0.08 msec after the J point). |
| Physical Functional Disability - Functional Capacity (Exercise Induced ST Segment Depression) | Baseline | Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. In electrocardiography, the ST segment connects the QRS complex and the T wave and has duration of 80 to 120 ms. It should be essentially level with the PR and TP segment. The normal ST segment has a slight upward concavity. Flat, downsloping, or depressed ST segment may indicate coronary ishcemia. Positive treadmill exercise stress test (\>1.0 mm horizontal / downsloping or \>1.5 upsloping ST segment depression measured 0.08 msec after the J point). |
| Quality of Life - Menopause Symptoms | Baseline | Quality of life assessed by menopausal symptoms and psychological questionnaires |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Hormone Replacement Therapy Hormone replacement therapy with 1 mg norethindrone/10 mcg thinyl estradiol (1/10 NA/EE). | 18 |
| Placebo 1 mg placebo. | 19 |
| Total | 37 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Withdrawal by Subject | 1 | 1 |
Baseline characteristics
| Characteristic | Hormone Replacement Therapy | Total | Placebo |
|---|---|---|---|
| Age, Continuous | 56 years STANDARD_DEVIATION 9 | 57.5 years STANDARD_DEVIATION 8 | 59 years STANDARD_DEVIATION 7 |
| Body Mass Index | 31 kg/m^2 STANDARD_DEVIATION 9 | 31 kg/m^2 STANDARD_DEVIATION 8 | 31 kg/m^2 STANDARD_DEVIATION 7 |
| Current HT use prior to entry Current HT use prior to entry | 6 participants | 14 participants | 8 participants |
| Current HT use prior to entry No HT prior to entry | 12 participants | 23 participants | 11 participants |
| Current Smoking No smoking | 16 participants | 33 participants | 17 participants |
| Current Smoking Smoking | 2 participants | 4 participants | 2 participants |
| Diastolic Blood Pressure | 76 mmHg STANDARD_DEVIATION 13 | 77 mmHg STANDARD_DEVIATION 11 | 78 mmHg STANDARD_DEVIATION 9 |
| Education College | 8 participants | 14 participants | 6 participants |
| Education High school or less | 10 participants | 23 participants | 13 participants |
| Fasting Blood Sugar | 93 mg/dl STANDARD_DEVIATION 17 | 93.5 mg/dl STANDARD_DEVIATION 18.5 | 94 mg/dl STANDARD_DEVIATION 20 |
| HDL-Cholesterol | 48 mg/dl STANDARD_DEVIATION 16 | 51 mg/dl STANDARD_DEVIATION 12.5 | 54 mg/dl STANDARD_DEVIATION 9 |
| History of Diabetes History of Diabetes | 4 participants | 9 participants | 5 participants |
| History of Diabetes No Diabetes | 14 participants | 28 participants | 14 participants |
| History of Dyslipidemia Dyslipidemia | 11 participants | 18 participants | 7 participants |
| History of Dyslipidemia Normal values | 7 participants | 19 participants | 12 participants |
| History of Hypertension Hypertension | 5 participants | 19 participants | 14 participants |
| History of Hypertension Normal blood pressure | 13 participants | 18 participants | 5 participants |
| LDL-Cholesterol | 120 mg/dl STANDARD_DEVIATION 51 | 122 mg/dl STANDARD_DEVIATION 44.5 | 124 mg/dl STANDARD_DEVIATION 38 |
| Pulse | 68 beats per minute STANDARD_DEVIATION 8 | 72 beats per minute STANDARD_DEVIATION 9.5 | 76 beats per minute STANDARD_DEVIATION 11 |
| Race/Ethnicity, Customized Nonwhite | 3 participants | 6 participants | 3 participants |
| Race/Ethnicity, Customized White | 15 participants | 31 participants | 16 participants |
| Sex: Female, Male Female | 18 Participants | 37 Participants | 19 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
| Systolic Blood Pressure | 130 mmHg STANDARD_DEVIATION 18 | 133 mmHg STANDARD_DEVIATION 18 | 136 mmHg STANDARD_DEVIATION 18 |
| Total Cholesterol | 195 mg/dl STANDARD_DEVIATION 47 | 200 mg/dl STANDARD_DEVIATION 43 | 205 mg/dl STANDARD_DEVIATION 39 |
| Triglycerides | 132 mg/dl STANDARD_DEVIATION 92 | 133 mg/dl STANDARD_DEVIATION 78 | 134 mg/dl STANDARD_DEVIATION 64 |
| Waist circumference | 92 cm. STANDARD_DEVIATION 17 | 92.5 cm. STANDARD_DEVIATION 16 | 93 cm. STANDARD_DEVIATION 15 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 0 / 18 | 0 / 19 |
| serious Total, serious adverse events | 2 / 18 | 0 / 19 |
Outcome results
Endothelial Dysfunction (FMD)
Endothelial dysfunction refers to altered vasoactive, anticoagulant, and anti-inflammatory properties of endothelium, and dysregulated vascular growth remodeling that results from a loss of nitric oxide (NO) bioactivity in the endothelium. Brachial Artery Reactivity Testing (BART), high-frequency ultrasonographic imaging of the brachial artery, evaluates flow-mediated vasodilation (FMD), an endothelium-dependent function. The technique provokes the release of nitric oxide, resulting in vasodilation that can be quantitated as an index of endothelial dysfunction. Flow-mediated vasodilation is typically expressed as the change in post-stimulus diameter as a percentage of the baseline diameter \[diameter after cuff deflation - baseline diameter / baseline diameter) x 100\].
Time frame: Baseline
Population: Brachial artery reactivity testing at baseline by treatment
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Hormone Replacement Therapy | Endothelial Dysfunction (FMD) | 8.2 percentage of pre-stimulus diameter | Standard Deviation 7.8 |
| Placebo | Endothelial Dysfunction (FMD) | 8.8 percentage of pre-stimulus diameter | Standard Deviation 7.3 |
Endothelial Dysfunction (FMD)
Endothelial dysfunction refers to altered vasoactive, anticoagulant, and anti-inflammatory properties of endothelium, and dysregulated vascular growth remodeling that results from a loss of nitric oxide (NO) bioactivity in the endothelium. Brachial Artery Reactivity Testing (BART), high-frequency ultrasonographic imaging of the brachial artery, evaluates flow-mediated vasodilation (FMD), an endothelium-dependent function. The technique provokes the release of nitric oxide, resulting in vasodilation that can be quantitated as an index of vasomotor function. Flow-mediated vasodilation is typically expressed as the change in post-stimulus diameter as a percentage of the baseline diameter \[diameter after cuff deflation - baseline diameter / baseline diameter) x 100\].
Time frame: 12 weeks
Population: Brachial artery reactivity testing at study exit by treatment
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Hormone Replacement Therapy | Endothelial Dysfunction (FMD) | 8.8 percentage of pre-stimulus diameter | Standard Deviation 5.3 |
| Placebo | Endothelial Dysfunction (FMD) | 7.3 percentage of pre-stimulus diameter | Standard Deviation 6.1 |
Inducible Myocardial Ischemia
Inducible myocardial ischemia measured by P-31 gated magnetic resonance cardiac spectroscopy (MRS) is reported as change (∆) in PCr/ATP ratio, with isometric submaximal handgrip stress. PCr/ATP ratio defined as (stress-\[average of rest and recovery periods\]) / average of rest and recover periods X 100, and expressed as % mean ± SD. For this trial, myocardial ischemia was pre-specified as a fall in quantitative PCR/ATP ratio \>20% from rest, and a lower value is considered indicative of greater ischemia.
Time frame: 12 weeks
Population: Among the 35 women, 28 baseline and 26 exit MRS results were technically adequate for spectral analyses with rest, handgrip exercise, and recovery spectra. A total of 24 women (13 drug, 11 placebo) had both baseline and exit P31's.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Hormone Replacement Therapy | Inducible Myocardial Ischemia | -7.7 percent change in PCR/ATP ratio | Standard Deviation 20.8 |
| Placebo | Inducible Myocardial Ischemia | 1.1 percent change in PCR/ATP ratio | Standard Deviation 9.7 |
Inducible Myocardial Ischemia
Inducible myocardial ischemia measured by P-31 gated magnetic resonance cardiac spectroscopy (MRS) is reported as change (∆) in PCr/ATP ratio, with isometric submaximal handgrip stress. PCr/ATP ratio defined as (stress-\[average of rest and recovery periods\]) / average of rest and recover periods X 100, and expressed as % mean ± SD. For this trial, myocardial ischemia was pre-specified as a fall in quantitative PCR/ATP ratio \>20% from rest, and a lower value is considered indicative of greater ischemia.
Time frame: Baseline
Population: Among the 35 women, 28 baseline and 26 exit MRS results were technically adequate for spectral analyses with rest, handgrip exercise, and recovery spectra. A total of 24 women (13 drug, 11 placebo) had both baseline and exit P31's.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Hormone Replacement Therapy | Inducible Myocardial Ischemia | -13.8 percent changed in PCR/ATP ratio | Standard Deviation 24.2 |
| Placebo | Inducible Myocardial Ischemia | -7.0 percent changed in PCR/ATP ratio | Standard Deviation 22.8 |
Physical Functional Disability - Functional Capacity (Exercise Induced ST Segment Depression)
Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. In electrocardiography, the ST segment connects the QRS complex and the T wave and has duration of 80 to 120 ms. It should be essentially level with the PR and TP segment. The normal ST segment has a slight upward concavity. Flat, downsloping, or depressed ST segment may indicate coronary ishcemia. Positive treadmill exercise stress test (\>1.0 mm horizontal / downsloping or \>1.5 upsloping ST segment depression measured 0.08 msec after the J point).
Time frame: Baseline
Population: Exercise stress testing at baseline by treatment
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Hormone Replacement Therapy | Physical Functional Disability - Functional Capacity (Exercise Induced ST Segment Depression) | -0.79 mm | Standard Deviation 0.78 |
| Placebo | Physical Functional Disability - Functional Capacity (Exercise Induced ST Segment Depression) | -0.79 mm | Standard Deviation 0.47 |
Physical Functional Disability - Functional Capacity (Metabolism Equivalents)
Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain.
Time frame: Exit (12 weeks)
Population: Exercise stress testing at exit (12 weeks) by treatment
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Hormone Replacement Therapy | Physical Functional Disability - Functional Capacity (Metabolism Equivalents) | 6.1 metabolism equivalents | Standard Deviation 2.4 |
| Placebo | Physical Functional Disability - Functional Capacity (Metabolism Equivalents) | 5.4 metabolism equivalents | Standard Deviation 2.5 |
Physical Functional Disability - Functional Capacity (Metabolism Equivalents)
Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain.
Time frame: Baseline
Population: Exercise stress testing at baseline by treatment
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Hormone Replacement Therapy | Physical Functional Disability - Functional Capacity (Metabolism Equivalents) | 6.1 metabolism equivalents | Standard Deviation 3 |
| Placebo | Physical Functional Disability - Functional Capacity (Metabolism Equivalents) | 5.8 metabolism equivalents | Standard Deviation 2.1 |
Physical Functional Disability - Functional Capacity (METs)
Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. A MET is defined as the resting metabolic rate, that is, the amount or oxygen consumet at rest, sitting quietly in a chair, approximately 3.5 ml O2 / kg / min (1.2 kcallmin for a 70-kg person). As such, work at METs requires twice the resting metabolism or 7.0 ml O2/kg/min, and so on.
Time frame: Baseline
Population: Exercise stress testing at baseline by treatment
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Hormone Replacement Therapy | Physical Functional Disability - Functional Capacity (METs) | 5.4 metabolism equivalents | Standard Deviation 2.6 |
| Placebo | Physical Functional Disability - Functional Capacity (METs) | 5.4 metabolism equivalents | Standard Deviation 1.8 |
Physical Functional Disability - Functional Capacity (METs)
Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. A MET is defined as the resting metabolic rate, that is, the amount or oxygen consumet at rest, sitting quietly in a chair, approximately 3.5 ml O2 / kg / min (1.2 kcallmin for a 70-kg person). As such, work at METs requires twice the resting metabolism or 7.0 ml O2/kg/min, and so on.
Time frame: Exit at 12 weeks
Population: Exercise stress testing at exit (12 weeks) by treatment
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Hormone Replacement Therapy | Physical Functional Disability - Functional Capacity (METs) | 6.1 metabolism equivalents | Standard Deviation 2.4 |
| Placebo | Physical Functional Disability - Functional Capacity (METs) | 5.4 metabolism equivalents | Standard Deviation 2.5 |
Physical Functional Disability - Functional Capacity (Stress Induced ST Segment Depression)
Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. In electrocardiography, the ST segment connects the QRS complex and the T wave and has duration of 80 to 120 ms. It should be essentially level with the PR and TP segment. The normal ST segment has a slight upward concavity. Flat, downsloping, or depressed ST segment may indicate coronary ishcemia. Positive treadmill exercise stress test (\>1.0 mm horizontal / downsloping or \>1.5 upsloping ST segment depression measured 0.08 msec after the J point).
Time frame: Exit (12 weeks)
Population: Exercise stress testing at exit (12 weeks) by treatment
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Hormone Replacement Therapy | Physical Functional Disability - Functional Capacity (Stress Induced ST Segment Depression) | -1.05 mm | Standard Deviation 0.98 |
| Placebo | Physical Functional Disability - Functional Capacity (Stress Induced ST Segment Depression) | -0.63 mm | Standard Deviation 0.29 |
Quality of Life - Health Survey
Quality of life assessed by cardiac symptoms and psychological questionnaires (SF 36 scale - Short Form Health Survey) The SF-36 includes one multi-item scale that assesses eight health concepts: 1) limitations in physical activities because of health problems; 2) limitations in social activities because of physical or emotional problems; 3) limitations in usual role activities because of physical health problems; 4) bodily pain; 5) general mental health (psychological distress and well-being); 6) limitations in usual role activities because of emotional problems; 7) vitality (energy and fatigue); and 8) general health perceptions. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
Time frame: 12 weeks
Population: SF-36 scale at exit by treatment
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Hormone Replacement Therapy | Quality of Life - Health Survey | Physical functioning | 59.4 units on a scale | Standard Deviation 23.5 |
| Hormone Replacement Therapy | Quality of Life - Health Survey | Role-physical | 58.8 units on a scale | Standard Deviation 37.4 |
| Hormone Replacement Therapy | Quality of Life - Health Survey | Role-emotional | 76.5 units on a scale | Standard Deviation 34.9 |
| Hormone Replacement Therapy | Quality of Life - Health Survey | Bodily pain | 54.5 units on a scale | Standard Deviation 23.6 |
| Hormone Replacement Therapy | Quality of Life - Health Survey | General health | 55.2 units on a scale | Standard Deviation 19.7 |
| Hormone Replacement Therapy | Quality of Life - Health Survey | Mental health | 66.4 units on a scale | Standard Deviation 19.6 |
| Hormone Replacement Therapy | Quality of Life - Health Survey | Vitality | 35.6 units on a scale | Standard Deviation 24.5 |
| Hormone Replacement Therapy | Quality of Life - Health Survey | Social functioning | 59.4 units on a scale | Standard Deviation 16 |
| Placebo | Quality of Life - Health Survey | Social functioning | 56.1 units on a scale | Standard Deviation 20.6 |
| Placebo | Quality of Life - Health Survey | Physical functioning | 44.4 units on a scale | Standard Deviation 29.5 |
| Placebo | Quality of Life - Health Survey | General health | 57.2 units on a scale | Standard Deviation 15.8 |
| Placebo | Quality of Life - Health Survey | Role-physical | 25.0 units on a scale | Standard Deviation 33.2 |
| Placebo | Quality of Life - Health Survey | Vitality | 41.2 units on a scale | Standard Deviation 18 |
| Placebo | Quality of Life - Health Survey | Role-emotional | 66.7 units on a scale | Standard Deviation 39.6 |
| Placebo | Quality of Life - Health Survey | Mental health | 69.3 units on a scale | Standard Deviation 18.8 |
| Placebo | Quality of Life - Health Survey | Bodily pain | 41.5 units on a scale | Standard Deviation 21.6 |
Quality of Life - Health Survey
Quality of life assessed by cardiac symptoms and psychological questionnaires (SF 36 scale - Short Form Health Survey) The SF-36 includes one multi-item scale that assesses eight health concepts: 1) limitations in physical activities because of health problems; 2) limitations in social activities because of physical or emotional problems; 3) limitations in usual role activities because of physical health problems; 4) bodily pain; 5) general mental health (psychological distress and well-being); 6) limitations in usual role activities because of emotional problems; 7) vitality (energy and fatigue); and 8) general health perceptions. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
Time frame: Baseline
Population: SF-36 scale at baseline by treatment
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Hormone Replacement Therapy | Quality of Life - Health Survey | Physical functioning | 60.8 units on a scale | Standard Deviation 27.5 |
| Hormone Replacement Therapy | Quality of Life - Health Survey | Role-physical | 54.2 units on a scale | Standard Deviation 41.3 |
| Hormone Replacement Therapy | Quality of Life - Health Survey | Role-emotional | 70.3 units on a scale | Standard Deviation 42.6 |
| Hormone Replacement Therapy | Quality of Life - Health Survey | Bodily pain | 53.3 units on a scale | Standard Deviation 21.4 |
| Hormone Replacement Therapy | Quality of Life - Health Survey | General health | 55.4 units on a scale | Standard Deviation 19.4 |
| Hormone Replacement Therapy | Quality of Life - Health Survey | Mental health | 66.7 units on a scale | Standard Deviation 20.6 |
| Hormone Replacement Therapy | Quality of Life - Health Survey | Vitality | 35.6 units on a scale | Standard Deviation 23.1 |
| Hormone Replacement Therapy | Quality of Life - Health Survey | Social functioning | 59.4 units on a scale | Standard Deviation 14.7 |
| Placebo | Quality of Life - Health Survey | Social functioning | 53.2 units on a scale | Standard Deviation 24.3 |
| Placebo | Quality of Life - Health Survey | Physical functioning | 43.8 units on a scale | Standard Deviation 27.4 |
| Placebo | Quality of Life - Health Survey | General health | 57.4 units on a scale | Standard Deviation 15.1 |
| Placebo | Quality of Life - Health Survey | Role-physical | 37.3 units on a scale | Standard Deviation 40.2 |
| Placebo | Quality of Life - Health Survey | Vitality | 42.9 units on a scale | Standard Deviation 20.4 |
| Placebo | Quality of Life - Health Survey | Role-emotional | 66.7 units on a scale | Standard Deviation 41.6 |
| Placebo | Quality of Life - Health Survey | Mental health | 65.7 units on a scale | Standard Deviation 19.9 |
| Placebo | Quality of Life - Health Survey | Bodily pain | 42.1 units on a scale | Standard Deviation 17.4 |
Quality of Life - Menopause Symptoms
Quality of life assessed by menopausal symptoms and psychological questionnaires
Time frame: 12 weeks
Population: Menopause Symptoms at exit by treatment
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Hormone Replacement Therapy | Quality of Life - Menopause Symptoms | Poor memory | 59 percent of participants |
| Hormone Replacement Therapy | Quality of Life - Menopause Symptoms | Vaginal dryness | 35 percent of participants |
| Hormone Replacement Therapy | Quality of Life - Menopause Symptoms | Hot flushes or flashing | 41 percent of participants |
| Hormone Replacement Therapy | Quality of Life - Menopause Symptoms | Avoiding intimacy | 24 percent of participants |
| Hormone Replacement Therapy | Quality of Life - Menopause Symptoms | Change in sexual desire | 35 percent of participants |
| Placebo | Quality of Life - Menopause Symptoms | Avoiding intimacy | 56 percent of participants |
| Placebo | Quality of Life - Menopause Symptoms | Poor memory | 78 percent of participants |
| Placebo | Quality of Life - Menopause Symptoms | Change in sexual desire | 67 percent of participants |
| Placebo | Quality of Life - Menopause Symptoms | Vaginal dryness | 67 percent of participants |
| Placebo | Quality of Life - Menopause Symptoms | Hot flushes or flashing | 89 percent of participants |
Quality of Life - Menopause Symptoms
Quality of life assessed by menopausal symptoms and psychological questionnaires
Time frame: Baseline
Population: Menopause Symptoms at baseline by treatment
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Hormone Replacement Therapy | Quality of Life - Menopause Symptoms | Poor memory | 76 percent of participants |
| Hormone Replacement Therapy | Quality of Life - Menopause Symptoms | Vaginal dryness | 44 percent of participants |
| Hormone Replacement Therapy | Quality of Life - Menopause Symptoms | Change in sexual desire | 50 percent of participants |
| Hormone Replacement Therapy | Quality of Life - Menopause Symptoms | Avoiding intimacy | 39 percent of participants |
| Hormone Replacement Therapy | Quality of Life - Menopause Symptoms | Hot flushes or flashing | 89 percent of participants |
| Placebo | Quality of Life - Menopause Symptoms | Avoiding intimacy | 37 percent of participants |
| Placebo | Quality of Life - Menopause Symptoms | Hot flushes or flashing | 68 percent of participants |
| Placebo | Quality of Life - Menopause Symptoms | Poor memory | 53 percent of participants |
| Placebo | Quality of Life - Menopause Symptoms | Change in sexual desire | 37 percent of participants |
| Placebo | Quality of Life - Menopause Symptoms | Vaginal dryness | 58 percent of participants |